MAPK3 and neoplasm: We measured PDAC tumor cell response to drugs targeting the PI3K or MAPK pathways using Omipalisib (PI3K pathway inhibitor), Trametinib (MAPK pathway inhibitor via ERK1/2), and SHP099 (MAPK pathway inhibitor via SHP2).